It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pyroptosis, a type of Gasdermin-mediated cell death, contributes to an exacerbation of inflammation. To test the hypothesis that GSDME-mediated pyroptosis aggravates the progression of atherosclerosis, we generate ApoE and GSDME dual deficiency mice. As compared with the control mice, GSDME−/−/ApoE−/− mice show a reduction of atherosclerotic lesion area and inflammatory response when induced with a high-fat diet. Human atherosclerosis single-cell transcriptome analysis demonstrates that GSDME is mainly expressed in macrophages. In vitro, oxidized low-density lipoprotein (ox-LDL) induces GSDME expression and pyroptosis in macrophages. Mechanistically, ablation of GSDME in macrophages represses ox-LDL-induced inflammation and macrophage pyroptosis. Moreover, the signal transducer and activator of transcription 3 (STAT3) directly correlates with and positively regulates GSDME expression. This study explores the transcriptional mechanisms of GSDME during atherosclerosis development and indicates that GSDME-mediated pyroptosis in the progression of atherosclerosis could be a potential therapeutic approach for atherosclerosis.
Macrophages have been shown to have an important function in atherosclerosis. Here the authors show that, in human atherosclerotic plaques and mouse models, GSDME and pyroptosis promote atherosclerosis and inhibition of these pathways could reduce pathology associated with atherosclerotic disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 The First Affiliated Hospital of Xi’an Jiaotong University, Department of Cardiovascular Medicine, Xi’an, China (GRID:grid.452438.c) (ISNI:0000 0004 1760 8119)
2 The First Affiliated Hospital of Xi’an Jiaotong University, Department of Cardiovascular Medicine, Xi’an, China (GRID:grid.452438.c) (ISNI:0000 0004 1760 8119); Ministry of Education, Xi’an Jiaotong University, Key Laboratory of Environment and Genes Related to Diseases, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)
3 Xi’an Jiaotong University, Department of Vascular Surgery, The First Affiliated Hospital, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)
4 Xi’an Jiaotong University, Department of Pharmacy, The First Affiliated Hospital, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)